Europeiska unionen - svenska - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - sunitinib - kapsel, hård - 25 mg - sunitinib 25 mg aktiv substans; propylenglykol hjälpämne; mannitol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sandoz a/s - sunitinib - kapsel, hård - 37,5 mg - sunitinib 37,5 mg aktiv substans; mannitol hjälpämne; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - sunitinib - kapsel, hård - 12,5 mg - propylenglykol hjälpämne; mannitol hjälpämne; sunitinib 12,5 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - sunitinib - kapsel, hård - 50 mg - propylenglykol hjälpämne; mannitol hjälpämne; sunitinib 50 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 1 g - meropenemtrihydrat 1,14 g aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - meropenemtrihydrat - pulver till injektions-/infusionsvätska, lösning - 500 mg - meropenemtrihydrat 570 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - esomeprazolmagnesium - enterotablett - 20 mg - sockersfärer hjälpämne; esomeprazolmagnesium 20,7 mg aktiv substans - esomeprazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - esomeprazolmagnesium - enterotablett - 40 mg - sockersfärer hjälpämne; esomeprazolmagnesium 41,4 mg aktiv substans - esomeprazol

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - oktreotidacetat - injektionsvätska, lösning - 100 mikrogram/ml - oktreotidacetat - mikrog aktiv substans - oktreotid